Viking Therapeutics, Inc.

NasdaqCM:VKTX 株式レポート

時価総額：US$5.9b

Viking Therapeutics マネジメント

マネジメント 基準チェック /24

Viking Therapeuticsの CEO はBrian Lianで、 Sep2012年に任命され、 の在任期間は 12.17年です。 の年間総報酬は$ 12.63Mで、 4.9%給与と95.1%のボーナス（会社の株式とオプションを含む）で構成されています。 は、会社の株式の1.71%を直接所有しており、その価値は$ 100.41M 。経営陣と取締役会の平均在任期間はそれぞれ5.3年と10.5年です。

主要情報

Brian Lian

最高経営責任者

US$12.6m

報酬総額

CEO給与比率4.9%
CEO在任期間12.2yrs
CEOの所有権1.7%
経営陣の平均在職期間5.3yrs
取締役会の平均在任期間10.5yrs

経営陣の近況

Recent updates

Viking Therapeutics: Too Much Excitement Around Oral VK2735, Even If It Met High Expectations

Nov 04

Viking Therapeutics: Lots Of Positives

Oct 28

Viking Therapeutics: Market Rightly Excited By GLP-1 Promise -- A Buy Ahead Of Data

Sep 25

Companies Like Viking Therapeutics (NASDAQ:VKTX) Can Afford To Invest In Growth

Sep 07
Companies Like Viking Therapeutics (NASDAQ:VKTX) Can Afford To Invest In Growth

Viking Therapeutics: GLP-1/GIP Receptor Agonist And Its Competitive Landscape

Aug 30

Viking Therapeutics: Better-Than-Expected Trial Timelines While Pipeline Expands

Jul 25

We Think Viking Therapeutics (NASDAQ:VKTX) Can Easily Afford To Drive Business Growth

Apr 26
We Think Viking Therapeutics (NASDAQ:VKTX) Can Easily Afford To Drive Business Growth

Viking Therapeutics: Future Weight Loss Heavyweight?

Apr 02

We're Hopeful That Viking Therapeutics (NASDAQ:VKTX) Will Use Its Cash Wisely

Jan 09
We're Hopeful That Viking Therapeutics (NASDAQ:VKTX) Will Use Its Cash Wisely

We're Not Very Worried About Viking Therapeutics' (NASDAQ:VKTX) Cash Burn Rate

Sep 21
We're Not Very Worried About Viking Therapeutics' (NASDAQ:VKTX) Cash Burn Rate

Viking Therapeutics (NASDAQ:VKTX) Is In A Good Position To Deliver On Growth Plans

Jun 07
Viking Therapeutics (NASDAQ:VKTX) Is In A Good Position To Deliver On Growth Plans

We're Not Very Worried About Viking Therapeutics' (NASDAQ:VKTX) Cash Burn Rate

Mar 05
We're Not Very Worried About Viking Therapeutics' (NASDAQ:VKTX) Cash Burn Rate

Viking Therapeutics: Playing Second Fiddle To Madrigal

Aug 30

We Think Viking Therapeutics (NASDAQ:VKTX) Can Afford To Drive Business Growth

Jul 13
We Think Viking Therapeutics (NASDAQ:VKTX) Can Afford To Drive Business Growth

Revisiting Viking Therapeutics

Apr 20

We Think Viking Therapeutics (NASDAQ:VKTX) Can Afford To Drive Business Growth

Apr 12
We Think Viking Therapeutics (NASDAQ:VKTX) Can Afford To Drive Business Growth

We Think Viking Therapeutics (NASDAQ:VKTX) Can Afford To Drive Business Growth

Dec 17
We Think Viking Therapeutics (NASDAQ:VKTX) Can Afford To Drive Business Growth

Viking Therapeutics: Remaining Bullish And Sticking To My Plan

Aug 27

Viking Therapeutics soars 11% on encouraging VK0214 data in rare metabolic disorder

Jun 17

Have Insiders Been Selling Viking Therapeutics, Inc. (NASDAQ:VKTX) Shares This Year?

Jan 13
Have Insiders Been Selling Viking Therapeutics, Inc. (NASDAQ:VKTX) Shares This Year?

Viking Therapeutics announces senior management appointments

Jan 06

Do Institutions Own Viking Therapeutics, Inc. (NASDAQ:VKTX) Shares?

Dec 09
Do Institutions Own Viking Therapeutics, Inc. (NASDAQ:VKTX) Shares?

Viking Therapeutics: Progressing Steadily, But Concerns Remain

Nov 29

CEO報酬分析

Viking Therapeutics の収益と比較して、Brian Lian の報酬はどのように変化したか？
日付総報酬給与会社業績
Sep 30 2024n/an/a

-US$99m

Jun 30 2024n/an/a

-US$97m

Mar 31 2024n/an/a

-US$94m

Dec 31 2023US$13mUS$615k

-US$86m

Sep 30 2023n/an/a

-US$81m

Jun 30 2023n/an/a

-US$74m

Mar 31 2023n/an/a

-US$72m

Dec 31 2022US$5mUS$612k

-US$69m

Sep 30 2022n/an/a

-US$62m

Jun 30 2022n/an/a

-US$59m

Mar 31 2022n/an/a

-US$57m

Dec 31 2021US$4mUS$594k

-US$55m

Sep 30 2021n/an/a

-US$54m

Jun 30 2021n/an/a

-US$50m

Mar 31 2021n/an/a

-US$44m

Dec 31 2020US$5mUS$577k

-US$39m

Sep 30 2020n/an/a

-US$36m

Jun 30 2020n/an/a

-US$32m

Mar 31 2020n/an/a

-US$31m

Dec 31 2019US$4mUS$525k

-US$26m

Sep 30 2019n/an/a

-US$24m

Jun 30 2019n/an/a

-US$24m

Mar 31 2019n/an/a

-US$23m

Dec 31 2018US$1mUS$485k

-US$22m

Sep 30 2018n/an/a

-US$21m

Jun 30 2018n/an/a

-US$20m

Mar 31 2018n/an/a

-US$19m

Dec 31 2017US$805kUS$440k

-US$21m

報酬と市場: Brianの 総報酬 ($USD 12.63M ) は、 US市場 ($USD 7.74M ) の同規模の企業の平均を上回っています。

報酬と収益: Brianの報酬は増加しましたが、会社は利益を上げていません。

CEO（最高経営責任者

Brian Lian (58 yo)

12.2yrs

在職期間

US$12,628,061

報酬

Dr. Brian Lian, Ph D., served as Director at Apricus Biosciences, Inc. He has been the Chief Executive Officer and President at Viking Therapeutics, Inc. since September 24, 2012. Dr. Lian has been an Inde...

リーダーシップ・チーム

名称ポジション在職期間報酬所有権
Brian Lian
President12.2yrsUS$12.63m1.71%
$ 100.4m
Gregory Zante
Chief Financial Officer5.3yrsUS$3.50m0.0010%
$ 60.4k
Marianne Mancini
Chief Operating Officer3.8yrsUS$3.51m0.18%
$ 10.8m
Michael Morneau
Vice President of Finance & Administration6.6yrsUS$619.56kデータなし
Geoffrey Barker
Senior Vice President of Pharmaceutical Development1.8yrsデータなしデータなし

5.3yrs

平均在職期間

58.5yo

平均年齢

経験豊富な経営陣: VKTXの経営陣は経験豊富で経験豊富です（平均在職期間は5.3年）。

取締役

名称ポジション在職期間報酬所有権
Brian Lian
President12.2yrsUS$12.63m1.71%
$ 100.4m
Scott Hecker
Scientific Advisorno dataデータなしデータなし
Matthew Foehr
Independent Director10.5yrsUS$169.37k0.10%
$ 5.9m
J. Singleton
Independent Director10.5yrsUS$192.77k0.0085%
$ 499.9k
Charles Rowland
Independent Director7.3yrsUS$189.62k0.027%
$ 1.6m
Alan Cherrington
Scientific Advisorno dataデータなしデータなし
G. Alexander Fleming
Scientific Advisorno dataデータなしデータなし
Jay Magaziner
Scientific Advisorno dataデータなしデータなし
David Bullough
Scientific Advisorno dataデータなしデータなし
Lawson MacArtney
Independent Chairman10.5yrsUS$222.72k0.043%
$ 2.5m
Stephan Kemp
Scientific Advisorno dataデータなしデータなし
S. Rouan
Independent Director5.3yrsUS$178.65k0%
$ 0

10.5yrs

平均在職期間

63.5yo

平均年齢

経験豊富なボード: VKTXの 取締役会 は経験豊富で 経験豊富 です ( 10.5年の平均在任期間)。